Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Phase 2
Recruiting
- Conditions
- Hepatocellular CarcinomaSolid Tumor, Adult
- Interventions
- Drug: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib
- Registration Number
- NCT04803318
- Lead Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Brief Summary
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
- Detailed Description
The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Recurrent/Refractory advanced solid tumors
- Age between 18 and 85 years
- Expected life expectancy is greater than three months
Exclusion Criteria
- Benign tumor
- Life expectancy is less than three months
- Serious medical commodities
- others
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Combination treatment of 3 inhibitors Combination of three inhibitors Trametinib, Everolimus and Lenvatinib Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.
- Primary Outcome Measures
Name Time Method Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment. up to 36 months
- Secondary Outcome Measures
Name Time Method Assessing overall survival 48 months Assessing overall time to survival.
Assessing progress free survival 48 months
Trial Locations
- Locations (1)
The Second Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China